Pharma BD Deal Intelligence
Ascidian Therapeutics and Exegenesis Bio entered a non-exclusive strategic agreement combining Ascidian's RNA exon editing technology with Exegenesis Bio's AAV capsid engineering and capsid discovery workflows. The companies will evaluate Exegenesis Bio capsids against the delivery requirements of individual RNA exon editing programs, with Ascidian executing resulting exon editor-capsid combinations. Ascidian has partnered and wholly owned programs in retinal, renal, neurological, neuromuscular and genetically defined diseases. Financial terms were not disclosed.
← Browse all deals · How we score deals
More: 2026 deals